Facilities & Capabilities

Contact Us

  • 5 distinct GMP facilities in Atlantic Canada 
    • Headquarters and 4 complex chemistry facilities in Charlottetown, Prince Edward Island
    •  Biologics manufacturing in Windsor, Nova Scotia
  • +25,000 m²  manufacturing facility space
  • 118,000 L of chemical reactor space (20 L to 18,000 L)
  • 64,000 L of fermentation bioreactor capacity (30 L to 17,000 L)
  • Various development and GMP manufacturing areas providing different types of capabilities, including:
    • Class 100,000 (ISO 8/ Grade D) and 10,000 (ISO 7/ Grade C) controlled suites
    • Highly Potent API Band 3 and 4 containment suites
    • Commercial synthetic API manufacturing
    • Commercial biologic drug substance production
    • Full biologics development and characterization
    • Multi-Reactor System and scale down high throughput setup 
    • Continuous processing/flow chemistry equipment
    • Analytical development and 24/7 quality control
  • Multiple qualified GMP storage areas (-80°C to 2-8°C) for raw materials, cell lines, and drug substances
slide2
slide3
slide4
slide5
slide6
slide7
slide8
slide9
slide10
slide11
slide12


Facility
Synthetic Small Molecules
Fermented Small Molecules
Highly Potent APIs
Bioreagents
Biologics
Regulatory Inspection History
Research & Development

17 Hillstrom Ave., PE

  • Lab
  • Pilot
  • Non-GMP Commercial scale
  • Lab
  • Pilot
  • Lab
  • Pilot
  • Commercial
  • Lab
  • Pilot, Non-GMP


Headquarters

11 Aviation Ave., PE

  • Pilot, GMP, Classified
  • Commercial GMP
  • Large-scale Commercial GMP
  • Pilot GMP
  • Commercial GMP
  • Lab
  • Pilot
  • Commercial
  • Commercial GMP


New API Facility

11 Aviation Ave., PE

  • Lab GMP
  • Large-scale Commercial GMP
Large Scale Biomanufacturing Facility

24 Ivey Lane, NS

  • Lab
  • Pilot
  • Clinical
  • Large-scale commercial
Dedicated Facility

29 McCarville St., PE

Dedicated Natural Extraction

SEO plus – Test

  • 20+ years at GSK, leading R&D activities on multiple vaccine programs
  • Recently held positions in industry include: Senior Director (Function Head), Protein Biochemistry; Director, Antigen Design & Prototype Production; and, Associate Director, Antigen Design and Protein Characterization.
  • Key areas of expertise are:
    • Process development of protein Biologics/Recombinant Antigens
    • Recombinant protein expression (mammalian, insect, yeast, bacterial)
    • Production/design of Viral Vectors, mRNA vaccines, Bacterial outer membrane vesicles
    • Protein Engineering and Structural Biology
    • Defining quality attributes, biophysical characterization of proteins, and analytical strategy
  • Post graduate degrees in Functional Genomics (Université Laval) and Bioinformatics (MIT); M. Sc. Microbiology and Immunology (Laval).
  • 25+ Patent & 5 Scientific Publications

Normand Blais – Senior Director Development & Innovation, Biologics

  • 20+ years at GSK, leading R&D activities on multiple vaccine programs
  • Recently held positions in industry include: Senior Director (Function Head), Protein Biochemistry; Director, Antigen Design & Prototype Production; and, Associate Director, Antigen Design and Protein Characterization.
  • Key areas of expertise are:
    • Process development of protein Biologics/Recombinant Antigens
    • Recombinant protein expression (mammalian, insect, yeast, bacterial)
    • Production/design of Viral Vectors, mRNA vaccines, Bacterial outer membrane vesicles
    • Protein Engineering and Structural Biology
    • Defining quality attributes, biophysical characterization of proteins, and analytical strategy
  • Post graduate degrees in Functional Genomics (Université Laval) and Bioinformatics (MIT); M. Sc. Microbiology and Immunology (Laval).
  • 25+ Patent & 5 Scientific Publications

Oliver Technow - Chief Executive Officer

  • Industry Master Degree from Frankfurt Chamber of Commerce, Frankfurt Germany.
  • More than 20 years of global pharmaceutical industry experience.
  • Held numerous leadership positions in commercial development, marketing and brand management, and lifecycle management and has extensive product launch and market access expertise in Europe and North America.
  • In 1997, joined Eisai GmbH in Frankfurt, Germany and in 2002, was appointed Director, CNS Business Unit; in 2006, was appointed Vice President, Head of Global Marketing for Eisai Inc. in Woodcliff Lake, NJ;  in 2011, was appointed Vice President, Established Products Business Unit; in 2013, was appointed President & General Manager for Eisai Limited in Mississauga, ON.
  • Appointed President of BIOVECTRA Inc., December 10, 2015.
  • Board Director for BIOTECanada
  • Member of the Steering Council of Innovative Medicines Canada (IMC)
  • In 2017, appointed to the Government of Canada’s Health/Bio-sciences Strategic Economic Table
  • In November 2019, promoted to Chief Executive Officer at BIOVECTRA
  • In June 2020, named new Chair of PEI BioAlliance Board of Directors